Abstract
drug-eluting stents for the treatment of ISR within the femoropopliteal segment at a single institution. Methods: Medical records of all patients at Scripps Clinic Torrey Pines treated for ISR with at least one drug eluting stent (Zilver PTX nitinol self-expanding stent, Cook Medical, Bloomington, IN) between 3/2013 until 9/2014 were reviewed. Patient demographics included age, Rutherford category, ABI, and associated comorbidities. Patient outcomes included stent patency, major adverse events, and survival. Results: Twenty-six patients with 29 ISR lesions were treated with a mean follow up of 11.2 ± 4.2 months. Before treatment, 93% of patients had Rutherford scores 3. At 6 months follow up, 90% of patients had Rutherford scores 1. Mean patient age was 75.8 ± 9.4. 53.8% of patients were females. The mean total lesion length was 154 mm. Procedural success was achieved in 100% of lesions with 2.2 ±1.4 stents placed per lesion. Primary patency was 93% at 6 months and 72% at 12 months. Two patients experienced major adverse events with amputation due to re-occlusion after 30 days. Conclusion: The treatment of ISR in the femoropopliteal segment with drug-eluting stents resulted in favorable outcomes in patency and clinical improvement.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
